.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,427,798

« Back to Dashboard

Claims for Patent: 5,427,798

Title: Controlled sustained release tablets containing bupropion
Abstract:A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride with the tablet having a surface area to volume ratio to effectively control bupropion hydrochloride release in the body.
Inventor(s): Ludwig; Jennie Sue G. (Greenville, NC), Bass, Jr.; William L. (Farmville, NC), Sutton, Jr.; Joel E. (Greenville, NC)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:08/105,447
Patent Claims: 1. A controlled sustained release tablet comprising 25 to 500 mg of bupropion hydrochloride and hydroxypropyl methylcellulose, the amount of hydroxypropyl methylcellulose to one part of bupropion hydrochloride being 0.19 to 1.1 and said tablet having a surface to volume ratio of 3:1 to 25:1 cm.sup.-1 and said tablet having a shelf life of at least one year at 59.degree. to 77.degree. F. and 35 to 60% relative humidity, said tablet releasing between about 20 and 60 percent of bupropion hydrochloride in water in 1 hour, between about 50 and 90 percent in 4 hours and not less than about 75 percent in 8 hours.

2. The tablet of claim 1, which contains glycine hydrochloride or cysteine hydrochloride in the amount of 0.027 to 0.27 parts by weight of the bupropion hydrochloride.

3. A controlled sustained release tablet comprising an admixture of 25 to 500 mg of bupropion hydrochloride particles, hydroxypropyl methycellulose and glycine hydrochloride or cysteine hydrochloride and having a surface to volume ratio of 3:1 to 25:1 cm.sup.-1.

4. The tablet of claim 1 wherein an instant release film coating is provided as an outer coating for the tablet.

5. The tablet of claim 1, which contains glycine hydrochloride or cysteine hydrochloride in the amount of 0.05 to 0.162 parts by weight of the bupropion hydrochloride.

6. A controlled sustained release tablet comprising an admixture of 50 to 150 mg of bupropion hydrochloride particles, hydroxypropyl methylcellulose, and cysteine hydrochloride and having a surface to volume ratio of 7:1 to 16:1 cm.sup.-1.

7. A controlled sustained release tablet comprising an admixture of 50 to 500 mg of bupropion hydrochloride particles, hydroxypropyl methylcellulose and glycine hydrochloride and having a surface to volume ratio of 7:1 to 16:1 cm.sup.1.

8. The tablet of claims 6 or 7 having a film coating thereon.

9. A controlled sustained release tablet of claim 1 or 7 comprising about 50 to 150 mg of bupropion hydrochloride, said tablet having surface area to volume ratio of 7:1 to 16:1 cm.sup.-1.

10. A controlled sustained release tablet of claim 6 or 7 comprising about 50 mg of bupropion hydrochloride, said tablet having a surface area to volume ratio between about 13:1 to 16:1 cm.sup.-1.

11. A controlled sustained release tablet of claim 6 or 7 comprising about 100 mg of bupropion hydrochloride, said tablet having a surface area to volume ratio of between about 9:1 to 12:1 cm.sup.-1.

12. A controlled sustained release tablet of claim 6 or 7 comprising about 150 mg of bupropion hydrochloride, said tablet having a surface area to volume ratio between about 7:1 to 10:1 cm.sup.-1.

13. A controlled sustained release tablet comprising an admixture of 50 mg of bupropion hydrochloride and hydroxyprophyl methylcellulose which after oral administration of a single one of said tablets in adult men produces plasma levels of bupropion as free base ranging between the minimum and maximum levels as shown in FIG. 4 over twenty four hours.

14. A controlled sustained release tablet comprising an admixture of 100 mg of bupropion hydrochloride and hydroxypropyl methylcellulose which after oral administration of a single one of said tablets in adult men produces plasma levels of bupropion as free base ranging between the minimum and maximum levels as shown in FIG. 5 over twenty four hours.

15. A controlled sustained release tablet comprising an admixture of 150 mg of bupropion hydrochloride and hydroxypropyl methylcellulose which after oral administration of a single one of said tablets in adult men produces plasma levels of bupropion as free base ranging between the minimum and maximum levels as shown in FIG. 6 over twenty four hours.

16. The tablet of claims 13, 14 or 15 in which an instant release film coating is provided thereover.

17. A sustained release tablet containing a mixture of (a) 50 mg of bupropion hydrochloride and (b) means for releasing between about 30 and 50 percent of bupropion hydrochloride in one hour, between about 70 and 95 percent in four hours and not less than 80 percent in 8 hours in distilled water said means comprising hydroxypropyl methylcellulose.

18. A sustained release tablet containing a mixture of (a) 100 mg of bupropion hydrochloride and (b) means for releasing between about 25 and 45% of bupropion hydrochloride in one hour, between 60 and 85% in 4 hours and not less then 80% in eight hours in distilled water said means comprising hydroxypropyl methylcellulose.

19. A sustained release tablet containing a mixture of (a) 150 mg of bupropion hydrochloride and (b) means for releasing about between 25 and 45% of bupropion hydrochloride in one hour, between about 60 and 85% in four hours and not less than 80% in eight hours in distilled water said means comprising hydroxypropyl methylcellulose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc